News
The clinical trial results will be used to expand Viome’s mRNA platform, which in May received FDA breakthrough device designation for identifying early signs of oral and throat cancers.
The industrial giant plans to retain a stake of almost 20% in GE Healthcare.
Cue received emergency use authorization for its at-home COVID-19 test in March and went public in September.
The new funding round brings the company's valuation to $4.6 billion.
The company said the latest round brings its total raise to $47 million.
The tool uses information about pain level, condition and current medication regimen to find an effective dose of opioids.
Third-party developers can use the platform to build their own products or update instruments.
The scheme is being run in partnership with government technology firm PUBLIC.
The pair aim to make AI-enhanced diagnostics accessible beyond hospital settings.
The two companies will also collaborate on a clinical study using AI mammography.